Regorafenib in Advanced and Refractory Gastrointestinal Cancers

Speakers:

Eric Van Cutsem,¹ Michael Ducreux,² Diether Lambrechts³

1. University Hospitals Leuven, Leuven, Belgium
2. Gustave Roussy Cancer Campus Grand Paris, Villejuif, France
3. VIB Vesalius Research Center, Leuven, Belgium

Disclosure:

Prof Eric Van Cutsem has received research funding from Amgen, Bayer, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, Roche, and Sanofi. Dr Diether Lambrechts has served on advisory boards for Roche, Sanofi, Bayer, and Boehringer-Ingelheim, and received speaker’s fees from Eli Lilly and Roche. Dr Michel Ducreux has received research funding from Roche, Chugai, and Pfizer, and has other substantive relationships with Celgene, Merck Serono, Amgen, Novartis, and Sanofi.

Acknowledgements:

Medical writing was provided by Ewen Legg, PhD, of Halcyon Medical Writing and was funded by Bayer.

Support:

Medical writing was provided by Ewen Legg, PhD, of Halcyon Medical Writing and was funded by Bayer.

Citation:

EMJ. 2016;1[3]:21-25. DOI/10.33590/emj/10311556. https://doi.org/10.33590/emj/10311556.

Keywords:

ESMO, European Society of Medical Oncology, WCGI, World Congress on Gastrointestinal Cancer

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.